Ophthalmology Times Europe E-News:
Having trouble viewing this e-mail? Click here.
You are subscribed to %%list.name%% as %%emailaddr%%.
Unsubscribe from this list.
Ophthalmology Times Europe E-News
Modern Medicine Network
 
 
 
 
TOP SEARCHES: OCT // Canaloplasty // AMD
In this issue
Cataract gene
Gene therapy
Glaucoma implant
Anti-inflammatory agent
Diagnosing melanoma
NicOx & Pfizer
Survey

Does the European Working Time Directive impact on your practice?
Novartis

Yes 25%
No 75%


You can now follow us on Twitter:
www.twitter.com/oteurope

Contact Us
Click here to contact Pamela Brook, editor.

Click here to contact Amelia Tope, associate editor.

Click here to contact Neil Hanley, sales manager.

 
AUGUST 19, 2009
Researchers uncover genetic link to age-related cataracts
Researchers in Cleveland have discovered the first gene associated with the formation of age-related cataracts. EphA2 encodes an enzyme that plays a role in the repair of proteins in the lens of the eye after they become damaged and clump together. More...
Gene therapy delivers bonus results
Partial sections of vision were recently restored to a blind woman's retina through the use of gene therapy. More...
Implant with potential to permanently treat glaucoma
OcumatRx, an early stage company that is developing a medical device that represents a new concept for the permanent treatment of patients with glaucoma, has announced the successful completion of clinical trials for their first device with favourable preliminary safety and tolerability. More...
Clinical trials show promise to help mydriasis during cataract surgery
Results from the Omeros Corporation for the Phase I/Phase II clinical trial of OMS302, a proprietary combination of an anti-inflammatory agent and an agent that causes pupil dilation (mydriasis) are said to be promising. More...
When can an eye growth transform into melanoma?
According to a report in the August issue of Archives of Ophthalmology, there are eight factors that may predict whether a choroidal nevus-a benign, flat, pigmented growth inside the eye and beneath the retina-may develop into melanoma. More...

NicOx reacquires rights to glaucoma agent from Pfizer
NicOx S.A. has signed an agreement with Pfizer Inc to reacquire the full development and commercialization rights to PF-03187207, which has completed two phase II studies in patients with primary open angle glaucoma and ocular hypertension. More...

product profile
Excimer laser for multiple applications
The ExciStar XS series from Coherent, Inc. represents a compact, economical excimer laser offering performance and lifetime characteristics. The air cooled ExciStar XS measures 0,08 m3, yet delivers pulse energies up to 12mJ at 248nm with an energy stability of <2% (1s), at repetition rates of 500 Hz. The use of Almeta XS tube design and all solid state pulser results in a product lifetime that lasts for more than 1 billion pulses than that of tube and optics. Read more...

You are subscribed to %%list.name%% as %%emailaddr%%. To unsubscribe from this list click here.

To ensure delivery to your Inbox, please add %%email.list%% to your address book. If you need help doing this, click here.

Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, please contact us by emailing magazines@superfill.com or by mail at Advanstar Communications, Advanstar House, Park West, Sealand Road, Chester, CH1 4RN, UK.